Company Overview of Aesica Pharmaceuticals Limited
Aesica Pharmaceuticals Limited provides pharmaceutical contract development and manufacturing services. The company offers potency drug substance and drug manufacturing services that include the production of highly potent active pharmaceutical ingredients; formulation development, analytics, and GMP services for pharmaceutical dosage forms that include tablets, capsules, liquids, suspensions, creams, ointments, and inhaled pharmaceuticals; and finished dose manufacturing services, such as wet granulation, tablet production, encapsulation, liquid manufacturing, temperature critical, blister packaging, and bottle packing. It serves pharmaceutical, biotech, and life science companies, as well ...
Quorum Business Park
Newcastle upon Tyne, NE12 8BS
Founded in 2004
Key Executives for Aesica Pharmaceuticals Limited
Chief Operations Officer and Managing Director of API
Head of Quality - Cramlington Facility
Group Marketing and Communications Director
Compensation as of Fiscal Year 2014.
Aesica Pharmaceuticals Limited Key Developments
Aesica Announces Board Appointments
Oct 20 14
Aesica announced the appointment of two senior business development positions. Detlef Behrens has been appointed to the role of Vice President, Business Development, Finished Dose with Sven Wrabletz joining as Business Development Director, Finished Dose. Detlef has overall responsibility for business development and for finished dose services, covering formulation development, bulk manufacturing and packaging with a full international remit across the Group. Sven is also responsible for finished dose development, manufacturing and packaging but with a geographic remit covering Northern Germany, Benelux and Eastern Europe. Both positions are based in Germany. Detlef reports directly to Ian Muir, Managing Director, Finished Dose and prior to working for Aesica, Detlef held senior BD roles at Piramal and Next Pharma. Sven Wrabletz reports to Detlef Behrens.
Aesica Introduces 3P’s Fill2Weight Dispensing System
Nov 4 13
Aesica has introduced 3P’s Fill2Weight dispensing system – suitable for all powder formulations including spray dried and lyophilised powders – to its Nottingham site, enabling increased flexibility and reduced time in ‘first in human’ clinical studies. The Fill2Weight system is widely acknowledged as the most flexible micro dosing system available to the market, with the technology able to dose a wide range of powders and can quickly be scaled up from clinical to commercial production. Aesica will be offering the system to customers as a tool that enables the direct filling of APIs in to capsules, syringes or bottles, eliminating the time and cost associated with developing a blended formulation. Developed to fill a target weight, rather than dispensing fixed volume, Fill2Weight dynamically measures and records the dispensed weight of all doses, allowing for compensation in powder property changes without the need for intervention or re-calibration. The flexibility offered by the platform means that the micro dosing system can be used across capsules, vials, blisters, injectables or inhalers and weighting resolutions as low as 10 µg (10x lower than the competitor). Consequently, Fill2Weight is usable with potent compounds. With the increased drive from clients and regulatory bodies for Quality by Design (QbD), the micro dosing system’s flexibility and repeatability ensures that experiments can be designed from laboratory scale right through to commercial supply, due to the platform’s modular design. Moreover, multi-track production settings limit process changes in the final stages of product development and provide tighter regulation of process controls. Quality is enhanced with reduced weight variability, lower rejection levels and 100% weight recording, meaning the system is suitable for real-time release, monitoring and recording. The system is configurable for doses between 2.5mg-500mg, with a dosing accuracy of <3% RSD and cycle feed times of less than two seconds. The 3P Fill2Weight can be fully sterilised which allows it to be used to aseptically fill re-constitutable powders in to bottles or syringes. This delivers a cost-effective, truly scalable alternative to ‘in-vial’ lyophilisation.
Aesica Announces £30 Million Expansion at Queenborough Manufacturing Site
Sep 19 13
Aesica announced the creation of a new high capacity manufacturing facility following a £30 million investment at its Queenborough, Kent site. The 10,000 sq. m expansion has been constructed for the production of dose medication used in treating one of the most common lifestyle diseases: Type 2 diabetes in adults. The commercial production at the facility will commence in November. This development will approximately double the site’s solid dose manufacturing capacity and represents a major investment in highly technical and specialist equipment. The facility will have a dedicated workforce of 55 technicians with the design of the facility allowing the current capacity to be more than doubled in the future, which would require a further additional 50 staff to be recruited.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|